Literature DB >> 24955170

Ataxin-3 expression correlates with the clinicopathologic features of gastric cancer.

Li-Xia Zeng1, Yong Tang2, Yun Ma1.   

Abstract

UNLABELLED: To investigate the expression of Ataxin-3 in human gastric cancer tissues and cell lines, and explore its clinical pathologic significance.
METHODS: The expression of Ataxin-3 in gastric cancer (n=536) and noncancerous gastric mucosa (n=312) was determined by immunohistochemistry and correlated to clinicopathologic features such as histologic differentiation and tumor size. The expression of Ataxin-3 protein in the human gastric cancer cell lines MKN45, SGC7901 and in normal human gastric epithelial cells (GES-1) was also evaluated by Western blot analysis. Quantitative real-time PCR was used to determine Ataxin-3 mRNA expression in human gastric cancer cell lines and tissues.
RESULTS: The expression of Ataxin-3 protein was decreased in the gastric cancer compared to noncancerous gastric tissue, and correlated with tumor size, Lauren classification, histologic differentiation, and mutant p53 protein (P < 0.05). Similarly, Ataxin-3 mRNA expression was decreased in the gastric cancers compared to the noncancerous gastric tissue. Ataxin-3 protein and mRNA expression was lower in MKN45, SGC7901 cells than in the normal GES-1 cells.
CONCLUSION: Decreased expression of Ataxin-3 may play an important role in gastric carcinogenesis and development of gastric cancer.

Entities:  

Keywords:  Ataxin-3; clinicopathologic features; gastric cancer

Year:  2014        PMID: 24955170      PMCID: PMC4057849     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  35 in total

1.  Polyglutamine-expanded ataxin-3 activates mitochondrial apoptotic pathway by upregulating Bax and downregulating Bcl-xL.

Authors:  An-Hsun Chou; Tu-Hsueh Yeh; Yu-Li Kuo; Yu-Cheng Kao; Mei-Jie Jou; Chia-Yu Hsu; Shu-Ru Tsai; Akira Kakizuka; Hung-Li Wang
Journal:  Neurobiol Dis       Date:  2005-08-19       Impact factor: 5.996

2.  Deubiquitinating function of ataxin-3: insights from the solution structure of the Josephin domain.

Authors:  Yuxin Mao; Francesca Senic-Matuglia; Pier Paolo Di Fiore; Simona Polo; Michael E Hodsdon; Pietro De Camilli
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-23       Impact factor: 11.205

3.  An overview of the cancer burden for primary care physicians.

Authors:  Michael Thun; Ahmedin Jemal; Carol Desantis; Bonny Blackard; Elizabeth Ward
Journal:  Prim Care       Date:  2009-09       Impact factor: 2.907

Review 4.  Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome.

Authors:  A Sigal; V Rotter
Journal:  Cancer Res       Date:  2000-12-15       Impact factor: 12.701

Review 5.  Targeting the ubiquitin-proteasome system for cancer therapy.

Authors:  Min Shen; Sara Schmitt; Daniela Buac; Q Ping Dou
Journal:  Expert Opin Ther Targets       Date:  2013-07-04       Impact factor: 6.902

6.  Report of incidence and mortality in China cancer registries, 2009.

Authors:  Wanqing Chen; Rongshou Zheng; Siwei Zhang; Ping Zhao; Guanglin Li; Lingyou Wu; Jie He
Journal:  Chin J Cancer Res       Date:  2013-02       Impact factor: 5.087

7.  Josephin domain of ataxin-3 contains two distinct ubiquitin-binding sites.

Authors:  Giuseppe Nicastro; Laura Masino; Veronica Esposito; Rajesh P Menon; Alfonso De Simone; Franca Fraternali; Annalisa Pastore
Journal:  Biopolymers       Date:  2009-12       Impact factor: 2.505

8.  Structural and functional analysis of ataxin-2 and ataxin-3.

Authors:  Mario Albrecht; Michael Golatta; Ullrich Wüllner; Thomas Lengauer
Journal:  Eur J Biochem       Date:  2004-08

9.  Ataxin-3 protects cells against H2O2-induced oxidative stress by enhancing the interaction between Bcl-X(L) and Bax.

Authors:  L Zhou; H Wang; P Wang; H Ren; D Chen; Z Ying; G Wang
Journal:  Neuroscience       Date:  2013-04-02       Impact factor: 3.590

10.  Basal and stress-induced Hsp70 are modulated by ataxin-3.

Authors:  Christopher P Reina; Barzin Y Nabet; Peter D Young; Randall N Pittman
Journal:  Cell Stress Chaperones       Date:  2012-07-10       Impact factor: 3.667

View more
  5 in total

Review 1.  Deubiquitinases in cancer.

Authors:  Rongbin Wei; Xiaodong Liu; Weixin Yu; Tianshu Yang; Wenping Cai; Junjun Liu; Xiao Huang; Guo-tong Xu; Shouliang Zhao; Jianhua Yang; Shangfeng Liu
Journal:  Oncotarget       Date:  2015-05-30

2.  The Machado-Joseph Disease Deubiquitinase Ataxin-3 Regulates the Stability and Apoptotic Function of p53.

Authors:  Hongmei Liu; Xiaoling Li; Guozhu Ning; Shu Zhu; Xiaolu Ma; Xiuli Liu; Chunying Liu; Min Huang; Ina Schmitt; Ullrich Wüllner; Yamei Niu; Caixia Guo; Qiang Wang; Tie-Shan Tang
Journal:  PLoS Biol       Date:  2016-11-16       Impact factor: 8.029

Review 3.  Intrinsic Disorder in Proteins with Pathogenic Repeat Expansions.

Authors:  April L Darling; Vladimir N Uversky
Journal:  Molecules       Date:  2017-11-24       Impact factor: 4.411

4.  Genetic polymorphisms in ataxin-3 and liver cirrhosis risk related to aflatoxin B1.

Authors:  Xing-Zhizi Wang; Xiao-Ying Huang; Jin-Guang Yao; Chao Wang; Qiang Xia; Xi-Dai Long
Journal:  Oncotarget       Date:  2018-02-19

5.  Downregulation of ATXN3 Enhances the Sensitivity to AKT Inhibitors (Perifosine or MK-2206), but Decreases the Sensitivity to Chemotherapeutic Drugs (Etoposide or Cisplatin) in Neuroblastoma Cells.

Authors:  Baocheng Gong; Jinhua Zhang; Zhongyan Hua; Zhihui Liu; Carol J Thiele; Zhijie Li
Journal:  Front Oncol       Date:  2021-07-12       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.